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Abstract
Background: Prescribing, monitoring and administration of medicines in care homes could be improved. Research
has identified the need for one person to assume overall responsibility for the management of medicines within
each care home. and shown that a pharmacist independent prescriber service is feasible in this context.
Aims and objectives: To conduct a cluster randomised controlled trial to determine the effectiveness and cost-
effectiveness of a pharmacist-independent prescribing service in care homes compared to usual general
practitioner (GP)-led care.
Objectives: To perform a definitive randomised controlled trial (RCT) with an internal pilot to determine the
intervention’s effectiveness and cost-effectiveness and enable modelling beyond the end of the trial.
Methods: This protocol is for a cluster RCT with a 3-month internal pilot to confirm that recruitment is achievable,
and there are no safety concerns. The unit of randomisation is a triad comprising a pharmacist-independent
prescriber (PIP) based in a GP practice with sufficient registered patients resident in one or more care homes to
allow recruitment of an average of 20 participants. In the intervention group, the PIP will, in collaboration with the
GP: assume responsibility for prescribing and managing residents’ medicines including medication review and
pharmaceutical care planning; support systematic ordering and administration in the care home, GP practice and
supplying pharmacy; train care home and GP practice staff; communicate with GP practice, care home, supplying
community pharmacy and study team.
The intervention will last 6 months. The primary outcome will be resident falls at 6 months. Secondary outcomes
include resident health-related quality of life, falls at 3 months, medication burden, medication appropriateness,
mortality and hospitalisations. A full health economic analysis will be undertaken. The target sample size is 880
residents (440) in each arm) from 44 triads. This number is sufficient to detect a decrease in fall rate from 1.5 per
individual to 1.178 (relative reduction of 21%) with 80% power and an ICC of 0.05 or less.
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Discussion: Recruitment is on-going and the trial should complete in early 2020. The trial results will have
implications for the future management of residents in care homes and the ongoing implementation of
independent pharmacist prescribing.
Trial registration: ISRCTN, ID: 17847169. Registered on 15 December 2017.
Keywords: Older people, Pharmacist prescribing, Care homes, Polypharmacy, Randomised controlled trial
Background
In 2012, UK care homes provided personal care and
healthcare for almost half a million residents in regis-
tered residential or nursing care homes [1]. Care home
residents are generally frail, have multiple morbidities
and are prescribed a significant number of regular medi-
cines. Furthermore, age-related complex morbidity
renders them particularly vulnerable to medication prob-
lems and errors. The Care Quality Commission identi-
fies the management of medicines as one area of care in
care homes that regularly requires review and continues
to fall below the expected standards. The landmark UK-
based Care Homes Use of Medicines Study (CHUMS)
published in 2009 [2] observed 256 residents in 55 care
homes. Almost 70% of residents experienced at least one
medication error on any given day. One hundred resi-
dents (39.1%) were identified as having one or more pre-
scribing errors including no strength or route of
medicine specified (20%), unnecessary medicine pre-
scribed (approximately 25%), and errors in dose or
strength (14.4%). Nearly a quarter of residents (57;
22.3%) experienced an administration error such as an
omission (11.8%, of all errors). Out of 218 potentially
harmful medicines which required biochemical monitor-
ing, 32 (14.7%) had an error.
Many of these medication-related problems were also
reported in a systematic review by Alldred et al. [3]
which considered interventions to optimise prescribing
for older people in care homes. Problems highlighted
were prescription of medicines that were no longer in-
dicated, medicines which interacted with concurrent
medication, sub-optimal doses, inadequate monitoring
and inappropriate duration. The inappropriate prescrip-
tion of anti-psychotic medicines in care homes, and
other medicines for example, benzodiazepines, non-
steroidal anti-inflammatory drugs and proton-pump in-
hibitors, is well documented [4]. This inappropriate
prescribing is known to be related to poor quality of
life, falls, strokes and increased mortality. In particular,
whilst falls are multifactorial in their causation it has
been noted that drugs are a modifiable risk factor and
periodic drug review should be a component of any
falls-reduction programme [5]. Consequently, effective
interventions are needed to monitor and discontinue
inappropriate therapy.
The CHUMS report [6] proposed that the fundamen-
tal failing in care homes was the lack of a healthcare
professional with overall continuing responsibility for
medicine management, and recommended that a
pharmacist should adopt this role working with a lead
general practitioner (GP) within each home. The Depart-
ment of Health (DH) Immediate Action Alert [7] arising
from CHUMS required primary care organisations, GPs
and community pharmacy contractors to establish ef-
fective joint working strategies to address the identified
concerns. The resultant predominant model of care is
that of a pharmacy team undertaking full medication re-
views in care homes on a yearly or biannual basis. Two
Cochrane reviews [3, 8] suggest that this model may be
sub-optimal and that more effective approaches to medi-
cine optimisation in this population are required.
Changes in United Kingdom (UK) legislation, enabling
suitably trained pharmacists to prescribe, provide an op-
portunity for pharmacist-independent prescribers (PIPs)
to assume the proposed central role in the care home
environment. Evidence from the UK suggests that PIPs
can prescribe safely and provide patient benefit [9]. Re-
cent government initiatives in all devolved UK nations
have supported the deployment of pharmacists in both
general practices and care homes [10–14]. However, to
date, there is no gold-standard randomised controlled
trial (RCT) evidence of the clinical or cost-effectiveness
of this approach.
The aim of the study described in this protocol is to
conduct a cluster RCT, with internal pilot, to compare
the clinical and cost-effectiveness of a Care Homes
Independent Pharmacist Prescribing Service (CHIPPS)
with usual care. This is the final stage of a programme
of work, divided into discrete work packages, following
the Medical Research Council (MRC) guidance on the
development and evaluation of complex interventions
[15] which has reviewed the literature to select appropri-
ate outcome measures [16], ascertained the views of
stakeholders [17], developed a needs-based PIP training
package (publication in preparation) and conducted a
non-randomised feasibility study [18].
Methods
This is a cluster RCT conducted in primary care involv-
ing participating GP-PIP-care home triads in four study
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locations linked geographically to the Universities of East
Anglia, Leeds, Aberdeen and Queen’s Belfast, (hereafter
referred to by the University identity). A complete list of
study sites is available from the Senior Programme
Coordinator Mrs. Laura Watts; L.Watts1@uea.ac.uk.
The objectives for the cluster RCT are:
 To use an embedded (internal) pilot study to
confirm:
the feasibility of recruiting sufficient GP
practices, PIPs, care homes and residents
the availability of data for primary outcome at
3 months
that there are no intervention-related safety
concerns
If the pilot is successful, to deliver a full RCT to:
 Describe the clinical effectiveness of the
intervention: PIPs assuming responsibility for
medicines’ management of elderly residents in care
homes
 To estimate the cost-effectiveness of the
intervention
The intervention
The intervention will be delivered by trained PIPs for a
period of 6 months. The training programme comprises
2 days of face-to-face instruction, time in practice to de-
velop relationships with the GP and care home staff, and
to address any self-assessed competency gaps supported
by a mentor, and a formal final sign-off by a GP, who is
independent of the research. The development and
evaluation of the training programme will be published
separately.
The intervention has been tested in a feasibility study
[18]. It involves the PIP, in collaboration with the care
home resident’s GP, assuming responsibility for man-
aging the medicines of the resident, including:
 Reviewing resident’s medication and developing and
implementing a pharmaceutical care plan
 Assuming prescribing responsibilities
 Supporting systematic ordering, prescribing and
administration processes with each care home, GP
practice and supplying pharmacy where needed
 Providing training in care home and GP practice
 Communicating with GP practice, care home,
supplying community pharmacy and study team
Details of the intervention to be delivered by the PIP
are in the CHIPPS Service Specification (Additional file 1)
which was developed in previous work packages.
The study PIPs will work closely with the care home
staff and the resident’s GP, and communicate regularly
with both parties. Once residents are recruited, the local
researcher will maintain regular contact with the PIP to
ensure adherence to study procedures. During the study
there will be a check of a random 20% sample of the
pharmaceutical care plans and associated resident
documents by a study geriatrician, to ensure clinical ap-
propriateness and safety. Additionally, should any prob-
lem arise, the geriatrician will discuss this with the
Programme (DW, RH) or Trial (CB, RH) Chief Investi-
gator or local Principal Investigator (DA,CB, CH, DW).
At the end of the study period the intervention will
cease unless the GP practice and care home mutually
agree to continue to deliver it outwith the framework of
the research programme.
The comparator will be usual GP-led care. Whilst
pharmacists may already be providing some services for
care homes, these are usually annual or biannual visits
and unlike the intensive approach proposed here. At the
end of the study period all PIPs in the control practices
will be offered access to the study training. Any medical
practices which employ pharmacists to provide services
to care homes of similar intensity to that which we
propose will be excluded.
Study participants
The inclusion and exclusion criteria for the study partic-
ipants are:
The PIP
Inclusion criteria:
 Registered as a PIP with regulating body (GPhC
(England and Scotland) or Pharmaceutical Society of
Northern Ireland (Northern Ireland))
 Following CHIPPS study training, can demonstrate
to their mentor and independent GP assessor
competence to deliver the service specification
 Ability to work flexibly and commit a minimum of
16 h a month to deliver the service for 6 months
Exclusion criteria:
 Substantive employment with the community
pharmacy (branch/store) which supplies medicines
to the care home with which the PIP would work, to
protect against conflict of interest
 Already providing an intensive service to the care
home, e.g. a monthly visit (or more frequently), and
provision of intensive medication-focussed services
GP practice
Inclusion criteria:
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 The GP practice must manage sufficient care home
residents to support recruitment of the target of
approximately 20 eligible participants1
Exclusion criteria: none
Care homes
Inclusion criteria:
 Care Quality Commission (CQC) in England, Care
Inspectorate in Scotland or Regulation and Quality
Improvement in Northern Ireland, registered
specialism as caring for adults aged over 65 years
 Primarily caring for residents aged over 65 years
 Associated with a participating GP practice (i.e. one
or more residents registered with a participating
practice)
Exclusion criteria:
 Care homes which receive regular (e.g. a monthly
visit or more frequently), from a pharmacist,
providing other intensive medication-focussed
services
 Care homes which receive regular (e.g. a monthly
visit or more frequently), from another healthcare
professional, providing other intensive medication-
focussed services
 Care homes which are currently under formal
investigation with the Care Quality Commission
(CQC) in England, Care Inspectorate in Scotland or
Regulation and Quality Improvement in Northern
Ireland
 Care homes that are participating in any other study
likely to affect the outcome of the CHIPPS trial (e.g.
falls intervention study, rehydration study, etc.)
Care home residents
Inclusion criteria:
 Under the care of the participating GP practice
 Aged 65 years or over
 Currently prescribed at least one regular medication
 They or their appropriate representative is/are able
to provide informed consent/assent2
 Permanently resident in care home (not registered
for respite care/temporary resident)
Exclusion criteria:
 Currently receiving end-of-life care, (equivalent to
yellow (stage C) of the Gold Standards Framework
prognostic indicator) [19]
 Have additional limitations on their residence (e.g.
held securely)
 Participating in another intervention research study
Study outcomes
The study outcomes and data sources are summarised
below.
Primary outcome
 Fall rate per person at 6 months as documented in
the care home falls’ record
Secondary outcomes
 Proxy resident EQ-5D-5 L (quality of life) at baseline,
3 months and 6 months [20]
 Face-to-face self-reported resident EQ-5D-5 L (for
participants with capacity) at baseline, 3 months and
6 months [20]
 Proxy Barthel Index (physical functioning)
completed at baseline, and 6 months by identified
member of care home staff [21]
 Fall rate per person in the past 3 months at baseline,
3 months and 6 months as documented in care
home records
 Health-service utilisation (and associated costs) in
the past 3 months at baseline and in the past 6
months at 6 months’ follow-up, collected from care
home and GP records
 Mortality
 Change in hospitalisation rate per person (baseline
rate defined as 3 months prior to randomisation
compared with hospitalisation rate at 6-month
follow-up) collected from care home records
 Drug Burden Index (DBI) [22] at baseline and 6months
with medication data collected from GP records
 Cost-effectiveness of the PIP intervention from the
perspective of the NHS and care home
In addition, in the internal pilot stage which is now com-
pleted, the following data (stop-go criteria) were collected.
 Quantification of interest from medical practices-
PIPs-care home(s) to confirm the viability of
planned target recruitment numbers and time line
 > 30% of eligible patients have been recruited (from
those invited in each home)
 > 80% of data are available at 3 months for falls data
 No significant intervention-related safety concerns
A detailed process evaluation is being conducted follow-
ing MRC guidance [23] and will be published separately.
1Based on earlier work, we anticipate a consent rate of 55% and so
would expect to invite approximately 35 residents/GP practice
2The study will recruit residents both with and without capacity
because this is representative of care home populations, where many
residents are without capacity, and to exclude such residents would
render the research ungeneralisable. In addition, all residents could
benefit from the intervention, and so residents without capacity should
not be denied the opportunity to participate
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Participant identification and recruitment
Recruitment and consent will be complex due to the
need to identify medical practices with a PIP, recruit
homes and then residents for each triad. Initially, PIPs
and GPs will be recruited concurrently, with the care
homes recruited subsequently, followed by the residents.
Copies of recruitment documentation to be used in
England and Northern Ireland are attached in Add-
itional file 2. Scottish versions required some slight
changes in terminology, to accommodate the different
regulations for adults with incapacity, and are available
on request.
PIP and GP recruitment
Eligible PIPs in each area will be identified using local
networks, and initial informal contact will be followed
by formal invitation to PIP and GP practice (letter of in-
vitation, Participant Information Sheet, Consent Form)
and consent. PIPs will be recruited, together with the
GP practice with whom they should ideally have an
already established close working relationship. Basic
demographic information about interested GP practices
and their linked care home (e.g. the resident mix, home
ownership) will be collected to allow purposive sampling
if numbers allow. However, if this does not provide suffi-
cient GP practice-PIP pairings, PIPs and GP practices
will be approached separately and linked before care
homes are approached.
Care home recruitment
The participating GP practice will approach one (or
more, if necessary) of their eligible care homes and invite
them to take part in the study. If the care home manager
expresses interest, they will be sent a formal invitation
pack by the local researcher (including a letter and In-
formation Sheet). If a care home declines participation,
the GP will contact another home and invite them to
participate. If there are insufficient residents in one
home, then up to two further homes can be recruited.
Where a home does not wish to participate, and there is
no alternative home, a different GP practice in that area
will be identified and recruited and the process to recruit
the care home(s) will be repeated.
Resident recruitment
GPs will identify from their lists of registered patients,
those resident in the participating care homes taking one
or more medications, and screen them against the study
inclusion and exclusion criteria. Reasons for any exclu-
sions will be recorded on a standard form collected by the
local researcher. Care home managers will hand out invi-
tation packs (invitation letter from GP, Participant Infor-
mation Sheet (spoken version if necessary) and consent
form) directly to potential resident participants. The care
home manager will visit each resident after at least 24 h,
and obtain verbal consent for the local researcher to be
allowed to approach them to discuss participation in the
study. For residents who are considered by the manager to
lack capacity, packs will be posted to the resident’s next of
kin. To minimise selection bias, packs will be distributed
in the order of the list of names from the GP.
The local researcher will meet with interested resi-
dents, administer the Capacity Assessment for Residents
Form (see Additional file 3) and, if appropriate, take fully
informed consent. For those without capacity, there are
country-specific regulations to adhere to for each of the
home nations; these are detailed in Table 1. The ap-
proach is in line with recommended practice [27].
If someone loses capacity during the 6 months of the
study, they will remain in the study. This is a specific
statement on the Consent Form: ‘I agree to continue
participating in the study if I lose capacity before the
end of the study’. If someone should lose capacity during
the study, continued participation will be confirmed with
the next of kin following the same procedures as for ini-
tial consent.
Table 1 Obtaining third-party consent for residents without
capacity in the three devolved home countries
England and Northern Ireland
A letter will be sent to the supporting relative/friend/potential consultee
from the GP, enclosing the Information Sheet and Advice Form for
signature. The Information Sheet explains the study and asks if, in their
opinion, their friend/relative would have wanted to participate, if they
had been able to decide this for themselves, and, if they felt that their
friend/relative would have participated, would they be willing to act as
consultee and give permission on their friend/relative’s behalf? The
potential consultee is asked to complete an Advice Form and send it
back within 2 weeks. If there is no response within 2 weeks, another
similar letter is sent, asking for return of the completed Advice Form
within 1 week, stating that, if this not returned the care home will
assume that the friend/relative cannot be a consultee and will then
identify someone for this role from within the care home; this person
will not be the care home manager and will be completely
independent of the study.
Capacity to consent is described in the Mental Capacity Act 2005 [24]
and involves using personal and nominated consultees. The assent
process is consistent with Alzheimer Europe Ethics of Dementia
Research [25] and has the support of Alzheimer’s UK. In Northern Ireland
there is currently no primary legislation on capacity (according to the
General Medical Council) and so decisions about medical treatment and
care when people lack capacity must be made in accordance with the
common law, which requires decisions to be made in a person’s best
interests. Therefore, in Northern Ireland, the procedures used in England
will be used.
Scotland
The letter requesting permission, on behalf of the resident, will be sent
to the resident’s Welfare Power of Attorney (WPoA), along with the
Information Sheet and Consent Form. If there is no response within 2
weeks, another similar letter is sent. If the WPoA returns the signed
Consent Form, then the resident will be recruited into the study. If the
WPoA does not return the Form, the resident will not be recruited.
In Scotland, capacity to consent is described in the Adults with
Incapacity Act (Scotland) 2000 [26] and involves a WPoA who is able to
give consent.
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At each follow up visit, the care home manager will
be asked if any participants have re-gained capacity.
Should anyone re-gain capacity during the course of
the study, and if the resident is willing, their personal
consent to continue will be obtained using the tem-
plate Resident Recovered Capacity documents, and in
England it would be with the original Patient Infor-
mation and Consent. It is made clear in the Partici-
pant Information Sheets that if residents decide not
to continue, all the information collected so far will
remain in the study, but no further information will
be collected.
The recruitment flow chart and participant time line
are shown in Figs 1 and 2 below.
Randomisation and blinding
Randomisation will be at practice level rather than the
home level in order to minimise contamination which
may occur if two homes were in the same practice and
one received the intervention whilst the other did not. It
is not appropriate to randomise at resident level as the
intervention is designed to affect medication-related pro-
cesses at an institutional (care home), as well as a resi-
dent, level and, therefore, control participants would not
be immune to its effects.
Blocked randomisation will be undertaken by geograph-
ical area, using a web-based electronic randomisation sys-
tem integrated into the study database. The triads will be
informed of their randomisation group by the Senior
Fig. 1 Recruitment flow chart
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Programme Coordinator. Local Principal investigators at
each geographical site will be informed of the allocations of
their triads, (CB, DW, DA, CH) and one of the trial co-CIs
(CB) will be informed of all allocations by coded emails.
The GP and care homes in each triad are blinded until the
care home residents have been recruited. The PIPs are un-
blinded once randomisation has been completed as the
intervention PIPs have to complete training and compe-
tency assessment prior to the intervention start. Due to the
nature of the intervention, study participants cannot be
blinded to the intervention. The local researchers will be
blinded until after care home residents have been recruited
and baseline data collection has been completed. Should
they inadvertently be unblinded they are asked to inform
the Senior Programme Coordinator. As the researcher may
or may not be correct in suspecting that they know the
group allocation their perceived unblinding is not con-
firmed by the Senior Programme Coordinator until after
baseline data have been collected. The potential unblinding
is noted on the non-conformance report which is reviewed
by the PSC and DMC. The trial statistician is advised of the
triads where there is potential unblinding and will assess
whether this appears to have resulted in any bias in report-
ing by comparison with triads where there was no reported
unblinding.
Data collection
Data, as specified earlier, will be collected, by the local
researcher, from GP practice and care home paper and/
or digital records. Data will be coded and entered into
either paper Case Record Forms (CRFs) or electronically
using tablets. Data entered on paper records will be sub-
sequently entered into a centrally held Norwich Clinical
Trials Unit (NCTU) CHIPPS REDCap [28] database by
local researchers. Data collected electronically will be
entered into the REDCap database at the time of data
collection if there is Internet connectivity, or if working
off-line, at the next time the device is synchronised. Data
will be protected using established NCTU procedures.
Fig. 2 Participant time line
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Data management
Data management is detailed in the Data Management
Plan version 1: 21 November.2017. Local research staff
will receive training in all aspects of data collection and
management. Identification logs, screening logs and en-
rolment logs will be kept at each of the four University
locations in a locked cabinet within a secured room. All
data will be handled in accordance with the General
Data Protection Regulations 2018. All participants (GPs,
care homes and residents) will be given a unique study
Participant Identification Number (PIN). Data will be
entered under this identification number onto the cen-
trally held database stored on the servers based at
NCTU. Access to the database will be controlled with
unique usernames and encrypted passwords, and re-
stricted to members of the CHIPPS study team, and ex-
ternal regulators if requested. The servers are protected
by firewalls and maintained according to best practice.
The physical location of the servers is protected by
CCTV and security door access.
The database and associated code lists have been de-
veloped by the Study Coordinators in conjunction with
NCTU. The database software (REDCap) provides a
number of features to help maintain data quality, includ-
ing: maintaining an audit trail, allowing custom valida-
tions on all data, allowing users to raise data-query
requests, and search facilities to identify validation fail-
ure/missing data.
Once data entry is complete the database will be
locked prior to any trial analysis or unblinding. The Data
Management Team will provide a read-only link for the
Trial Statistician to access the data. After completion of
the study the database will be retained on the servers of
NCTU for on-going analysis, for 10 years.
The screening and enrolment logs will remain at the
care home. For recruitment monitoring purposes,
identifiable patient information will be redacted, and
pseudoanonymised copies of these logs being taken to
the research office. Following consent, identifiable (con-
sented participants only) screening data, linked to the
Participant Identification Number, will be held locally at
the University research office, in a locked filing cabinet.
After completion of the study the identification, screen-
ing and enrolment logs will be securely archived at each
University research office for 10 years, unless otherwise
advised by NCTU.
Sample size
A sample size of 880 (440 in each arm) would detect a
decrease in fall rate from 1.50 per individual over 6
months to 1.178 with 80% statistical power. These as-
sumptions are based upon data from the CAREMED
[29] study, which found a fall rate of 1.5 per individual
over a 6-month period and an intraclass correlation
coefficient (ICC) no greater than 0.07 for the endpoint
of interest. The detectable difference (from 1.5 to 1.178)
is a relative reduction of 21% which is half that detected
within a UK-based, pharmacist-led medication review
service provided to care homes [30]. The CAREMED
trial indicated a mortality rate of 33% and further loss to
follow-up of 5% over 12 months. Thus, a reasonable esti-
mate of total losses due to mortality or other reasons
over 6 months would be 20%, and is taken into account
in the above. However, we will use data, where possible,
up to the point at which someone withdraws from the
study.
To recruit 880 resident participants there will be a re-
cruitment target of 44 triads, with a mean of 20 partici-
pants from each, a loss rate of no more than 20% and an
≤ ICC of 0.05.
Statistical methods
An intention-to-treat analysis will be conducted. The
primary outcome (‘falls per resident’) will mostly likely
follow a Poisson distribution and a between-group com-
parison to estimate the difference in falls will be made
using a Poisson Regression model. This model will in-
clude baseline fall rate, prognostic variables (specified
prior to analysis) and group as a fixed factor. The unit of
analysis will be the individual participant but, due to the
study design incorporating ‘clustering’ these unit out-
comes are likely to be correlated. Therefore, a General-
ised Estimation Equation (GEE) approach will be used.
The Poisson assumption will be assessed with ‘fit’ statis-
tics and, if appropriate, a Zero Inflated Poisson, or a
Poisson model with an over-dispersion term will be con-
sidered. An analogue GEE model will be used for sec-
ondary outcomes, with an appropriate change to the
error distribution (e.g. Normal). The estimate of the
between-group difference will be provided with a 95%
confidence interval and tested at the 5% significance
level.
There are currently no plans for any subgroup
analyses.
Safety reporting of Serious Adverse Events
The processes for the recording of SUSARs (Sudden
Unexpected Serious Adverse Events), SAEs (Serious
Adverse Events) and AEs (Adverse Events) and near
misses in PIP documentation, GP and care home re-
cords, notification to NCTU, CI review, expedited and
periodic reporting to REC will be documented in the
study-specific Safety Management Plan.
For the purposes of this trial, SAEs are defined as
inpatient hospitalisation and death. The expedited, i.e.
immediate reporting is required if they are:
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 related to the study (i.e. they resulted from the
intervention) and
 unexpected (referred to hereafter as SUSARs)
A mixture of prospective and retrospective SUSAR no-
tification will be used.
Prospective: from the beginning of the intervention
until 30 days after the intervention ends GPs will be
asked to report SUSARs immediately via a SUSAR Form
to a dedicated NCTU safety email address.
Retrospective: a systematic retrospective collection of
SAEs will be conducted in both intervention and control
practices, whereby the NCTU Trial Manager will contact
every participating care home once a month and ask
about any SAEs. Deaths and hospitalisations in both
arms will also be reported to the REC via the annual
report.
The causality assessment of the SAE should be given
by the GP. If the GP identifies a positive causality (i.e.
the SAE is linked to the PIP intervention and is, there-
fore, a SUSAR) then this is signed off by the CI. The GP
must assess the causality of all SAEs in relation to the
PIP intervention using the definitions in the table below.
If the event is classified as ‘serious’ and assessed as being
related to the PIP intervention then a SUSAR Form
must be completed and NCTU notified within 24 h.
All staff involved in the care of study participants (i.e.
PIPs, care home staff, any other healthcare professionals)
will also be asked to report, immediately, to a separate
dedicated email address (chipps.safety@uea.ac.uk), any
events about which they are concerned. NCTU can be
notified of any further safety concerns or near misses by
all staff involved in the care of study participants via a
study-specific safety email address Table 2.
Trial management
The trial is overseen by a Trial Management Group
(TMG) comprising the Programme Chief Investigator,
The Trial Co-Chief Investigators, the local Principal In-
vestigators, the Senior Programme Manager, the NCTU
Manager and the Programme Administrator. The trial is
advised by a Programme Steering Committee (PSC)
which provides expert oversight of the trial, making
decisions as to the future continuation (or otherwise) of
the trial, by monitoring recruitment rates, approving
proposals by the TMG concerning any change to the de-
sign of the trial, as well as receiving letters of feedback
from the independent Data Monitoring Committee
(DMC). The DMC comprises a statistician, an academic
pharmacist with an interest in patient safety, and an aca-
demic GP (Chair) with extensive trials’ experience. The
DMC has a remit to monitor the safety of the trial
participants through examination of trial safety and
efficacy data, thereby providing advice to the Chair of
the Programme Steering Committee (PSC). The DMC
Chair informs the Chair of the PSC if, in the view of
the DMC, one trial arm is clearly indicated or contra-
indicated (for all participants or a particular category
of participants), and there is a reasonable expectation
that this new evidence would materially influence pa-
tient management.
There is a study Quality Management and Monitoring
Plan (version 2: 1 June.2018) which details the proce-
dures for quality control and data monitoring by the
NCTU. The study will also be subject to random moni-
toring by the host Universities and local Research and
Development Departments.
Discussion
The internal pilot study confirmed the feasibility of all study
processes and no safety concerns were identified. The re-
sults will be reported in full when the main trial findings
are published. Resident recruitment is ongoing and on tar-
get. The trial is expected to complete in early 2020. The
TMG is grateful for the support of the TSC and DMC who
have confirmed that to date there are no concerns.
The study should provide important information on
the clinical and cost-effectiveness of involving pharma-
cists in general practices and care homes –a policy being
widely rolled out across all home nations but with no
RCT of evidence. The trial is part of a programme of
work, part of which has been to develop a training
programme for pharmacists involved in care homes and
this will be made publicly available. The study also in-
cludes a detailed process evaluation and, taken together
with the trial results, the findings should allow recom-
mendations to be made about the optimum way to roll
out and manage this wider role for pharmacists. At a
time when the UK population is ageing, the results will
be relevant both to care home residents and frail,
community-dwelling older adults (Additional file 4).
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3827-0.
Additional file 1. Service specification.
Table 2 Serious Adverse Event (SAE) causality definitions
Event type Causality
assessment
Description
SAE Unrelated There is no evidence or rationale
for any causal relationship
SUSAR (Sudden
Unexpected Serious
Adverse Event)
Likely to be
related
There is evidence, and a
rationale, to suggest a causal
relationship and other possible
contributing factors can be ruled
out
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Additional file 2. Study recruitment documentation.
Additional file 3. Capacity assessment for residents.
Additional file 4. SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents.
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